肿瘤免疫微环境作为肝细胞癌发展的新治疗靶点
Tumor Immune Microenvironment as a New Therapeutic Target for Hepatocellular Carcinoma Development.
作者信息
Kim Eunjeong
机构信息
BK21 FOUR KNU Creative BioResearch Group, School of Life Sciences, Kyungpook National University, Daegu 41566, Korea.
出版信息
Dev Reprod. 2023 Dec;27(4):167-174. doi: 10.12717/DR.2023.27.4.167. Epub 2023 Dec 31.
Abstract
Development of hepatocellular carcinoma (HCC) is driven by a multistep and long-term process. Because current therapeutic strategies are limited for HCC patients, there are increasing demands for understanding of immunotherapy, which has made technological and conceptual innovations in the treatment of cancer. Here, I discuss HCC immunotherapy in the view of interaction between liver resident cells and immune cells.
摘要
肝细胞癌（HCC）的发生是一个多步骤的长期过程。由于目前针对HCC患者的治疗策略有限，人们对免疫疗法的理解需求日益增加，免疫疗法在癌症治疗方面带来了技术和概念上的创新。在此，我从肝驻留细胞与免疫细胞相互作用的角度探讨HCC免疫疗法。
相似文献
1
Tumor Immune Microenvironment as a New Therapeutic Target for Hepatocellular Carcinoma Development.
Dev Reprod. 2023 Dec;27(4):167-174. doi: 10.12717/DR.2023.27.4.167. Epub 2023 Dec 31.
2
Current insights into the hepatic microenvironment and advances in immunotherapy for hepatocellular carcinoma.
Front Immunol. 2023 May 18;14:1188277. doi: 10.3389/fimmu.2023.1188277. eCollection 2023.
3
Hepatocellular Carcinoma Tumor Microenvironment and Its Implications in Terms of Anti-tumor Immunity: Future Perspectives for New Therapeutics.
J Gastrointest Cancer. 2021 Dec;52(4):1198-1205. doi: 10.1007/s12029-021-00725-8. Epub 2021 Oct 8.
4
Strategies to Improve the Antitumor Effect of Immunotherapy for Hepatocellular Carcinoma.
Front Immunol. 2021 Nov 26;12:783236. doi: 10.3389/fimmu.2021.783236. eCollection 2021.
5
New Therapeutics for HCC: Does Tumor Immune Microenvironment Matter?
Int J Mol Sci. 2022 Dec 27;24(1):437. doi: 10.3390/ijms24010437.
6
[Strategies and challenges of immunotherapy for hepatocellular carcinoma].
Zhonghua Gan Zang Bing Za Zhi. 2020 Jun 20;28(6):457-460. doi: 10.3760/cma.j.cn501113-20200602-00288.
7
Identification of a tumour immune barrier in the HCC microenvironment that determines the efficacy of immunotherapy.
J Hepatol. 2023 Apr;78(4):770-782. doi: 10.1016/j.jhep.2023.01.011. Epub 2023 Jan 26.
8
Bibliometric study of immunotherapy for hepatocellular carcinoma.
Front Immunol. 2023 Aug 4;14:1210802. doi: 10.3389/fimmu.2023.1210802. eCollection 2023.
9
Immune System and Hepatocellular Carcinoma (HCC): New Insights into HCC Progression.
Int J Mol Sci. 2023 Jul 14;24(14):11471. doi: 10.3390/ijms241411471.
10
Tumor-Associated Macrophages in Hepatocellular Carcinoma: Friend or Foe?
Gut Liver. 2021 Jul 15;15(4):500-516. doi: 10.5009/gnl20223.
本文引用的文献
1
The Functional Roles of Immune Cells in Primary Liver Cancer.
Am J Pathol. 2022 Jun;192(6):826-836. doi: 10.1016/j.ajpath.2022.02.004. Epub 2022 Mar 23.
2
The Role of Tumor Associated Macrophages in Hepatocellular Carcinoma.
J Cancer. 2021 Jan 1;12(5):1284-1294. doi: 10.7150/jca.51346. eCollection 2021.
3
Combination therapy with dendritic cell vaccine and programmed death ligand 1 immune checkpoint inhibitor for hepatocellular carcinoma in an orthotopic mouse model.
Ther Adv Med Oncol. 2020 Jun 10;12:1758835920922034. doi: 10.1177/1758835920922034. eCollection 2020.
4
Metabolic Hallmarks of Hepatic Stellate Cells in Liver Fibrosis.
Cells. 2019 Dec 20;9(1):24. doi: 10.3390/cells9010024.
5
From bench to bed: the tumor immune microenvironment and current immunotherapeutic strategies for hepatocellular carcinoma.
J Exp Clin Cancer Res. 2019 Sep 9;38(1):396. doi: 10.1186/s13046-019-1396-4.
6
Current perspectives on the immunosuppressive tumor microenvironment in hepatocellular carcinoma: challenges and opportunities.
Mol Cancer. 2019 Aug 29;18(1):130. doi: 10.1186/s12943-019-1047-6.
7
The immunobiology of hepatocellular carcinoma in humans and mice: Basic concepts and therapeutic implications.
J Hepatol. 2020 Jan;72(1):167-182. doi: 10.1016/j.jhep.2019.08.014. Epub 2019 Aug 23.
8
Hepatocellular Carcinoma.
N Engl J Med. 2019 Apr 11;380(15):1450-1462. doi: 10.1056/NEJMra1713263.
9
Biological heterogeneity and versatility of cancer-associated fibroblasts in the tumor microenvironment.
Oncogene. 2019 Jun;38(25):4887-4901. doi: 10.1038/s41388-019-0765-y. Epub 2019 Feb 28.
10
Regulatory T cells in cancer immunosuppression - implications for anticancer therapy.
Nat Rev Clin Oncol. 2019 Jun;16(6):356-371. doi: 10.1038/s41571-019-0175-7.
Zotero 插件